How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak

Immunocore Extends TCR Therapy Into Solid Tumors

Immunocore’s ImmTAX platform engineers off-the-shelf bispecific T-cell receptor therapies designed to redirect T cells toward diseased cells. In cancer, that gives the company a way to pursue targets inside solid tumors that have historically been difficult to address.

Kimmtrak provided the first commercial validation. Approved in 2022 for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma, the drug is approved in 39 countries and launched in more than 30.

IMCR Makes Brenetafusp Its Next Growth Pillar

Brenetafusp is the lead PRAME-A02 ImmTAC bispecific candidate and the clearest test of Immunocore’s broader oncology ambitions. The registrational phase III PRISM-MEL-301 study is evaluating brenetafusp with Opdivo, from Bristol Myers BMY, for first-line advanced cutaneous melanoma.

Updated phase I/II data added support for that program. In heavily pretreated HLA-A*02:01-positive advanced melanoma patients, brenetafusp monotherapy showed an 87% six-month overall survival rate, a 57% 12-month overall survival rate and a 52% disease-control rate.

Immunocore Broadens Its Oncology Pipeline

Brenetafusp is also being studied across other tumor types, including ovarian cancer and non-small cell lung cancer. These efforts extend the platform into indications that are far larger than metastatic uveal melanoma and more commercially competitive.

Earlier programs target colorectal cancer and other gastrointestinal cancers. Success across those areas would not only add potential future revenue sources but also strengthen the case that ImmTAC technology can work across multiple solid tumor settings.

IMCR Moves Into Infectious and Autoimmune Diseases

Immunocore is not limiting its platform strategy to oncology. The company’s pipeline includes clinical-stage infectious disease programs, reflecting an effort to apply T-cell receptor expertise beyond cancer.

The company also plans phase I development of IMC-S118AI, an autoimmune candidate. That move is early, but it signals that Immunocore is testing whether targeted T-cell redirection can support a broader therapeutic business over time.

Immunocore Faces a Competitive Expansion Test

The expansion strategy carries real competitive risk. In larger oncology markets, Immunocore will face checkpoint inhibitors, cell therapies, bispecific antibodies and other T-cell receptor approaches backed by companies with deeper resources and commercial infrastructure.

Bristol Myers already has a major oncology presence through Opdivo, while Adaptimmune Therapeutics ADAPY is another company centered on engineered T-cell receptor therapies for cancer. That backdrop makes clinical differentiation essential for IMCR.

The bottom line is balanced. Kimmtrak generated $400 million in 2025 revenues, up 29%, and first-quarter 2026 revenues rose 14% to $106.7 million. Still, Kimmtrak remains the company’s only marketed product, keeping diversification important.

A neutral assessment fits the mix of platform potential and execution risk.

IMCR’s Zacks Rank

Immunocore currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research